• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerogen inks partnership to deliver COVID-19 vaccine with its mesh aerosol delivery tech

December 13, 2021 By Sean Whooley

Aerogen_Solo CanSinoBio
[Image from Aerogen]
Aerogen and CanSinoBio announced today that they entered a partnership to deliver the latter’s COVID-19 vaccine with Aerogen’s technology.

Galway, Ireland-based Aerogen’s proprietary vibrating mesh aerosol drug delivery technology will be used to deliver CanSinoBio’s recombinant novel coronavirus vaccine — Convidecia — under the development and commercial supply partnership. Commercial terms for the partnership were not disclosed.

The aerosolized vaccine from Tianjin, China-based CanSinoBio is directly inhaled through a cup dispenser in the patient’s airway. Aerogen said in a news release that the route mimics the natural infection pathway of the COVID-19 virus and may create additional benefits through generating mucosal immunity.

Aerogen touted interim results from Phase 3 clinical trials conducted by CanSinoBio that demonstrated an efficacy of 95.47% for preventing severe disease 14 days after a single-dose vaccination.

The company said inoculation through the inhaled aerosol route requires a smaller volume of vaccine to be used, providing the capacity to offer more access than would be possible with an injectable approach.

CanSinoBio is preparing an application for commercial authorization for its vaccine in China, with more clinical trials being prepared for other geographies.

“The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination,” Aerogen CEO & Founder John Power said in the release. “The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Aerogen, CanSinoBio, coronavirus, COVID-19

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS